Meeting Abstract

Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX)


AutorenlisteSchumacher, Falk; Mrdenovic, Nikola; Scheicht, Dennis; Pons-Kuehnemann, Joern; Scheibelhut, Christine; Strunk, Johannes

Jahr der Veröffentlichung2022

Seiten357-358

ZeitschriftDer Internist

Bandnummer63

HeftnummerSUPPL 3

ISSN0020-9554

eISSN1432-1289

VerlagSpringer



Autoren/Herausgeber




Zitierstile

Harvard-ZitierstilSchumacher, F., Mrdenovic, N., Scheicht, D., Pons-Kuehnemann, J., Scheibelhut, C. and Strunk, J. (2022) Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX), Der Internist, 63(SUPPL 3), pp. 357-358

APA-ZitierstilSchumacher, F., Mrdenovic, N., Scheicht, D., Pons-Kuehnemann, J., Scheibelhut, C., & Strunk, J. (2022). Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX). Der Internist. 63(SUPPL 3), 357-358.



Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-02-04 um 00:02